Company Profile
Updated: 24-DEC-09CSF S.A.S.
International subsidiary
ZI Rte. de Paris, Mondeville, F-14120, France
()33 02 31 70 60 00, 33 01 31 70 60 36 fax, http://www.carrefour.com
Primary SIC: Department Stores, Primary NAICS: Department Stores (except Discount Department Stores)
Description: Retail: Operation of supermarkets
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Study results from S.R. Brozell and colleagues in the area of physical chemistry published.
Chemicals & Chemistry; 1/8/2010; 606 words; ...N-alpha((S-max + 1)(2) - S-min(2)) N-alpha is the number...nonlinear arc factor parameters, and S-min and S-max, tire respectively the minimum...correspond to an underlying linear full-CI CSF expansion dimension of over 10(75...
Research from N. Muthukumar and co-authors provides new data about spinal cord disease.(Report)
Biotech Week; 1/6/2010; 1004 words; ...part of the study. Nurick's grading was used to assess...developed cerebrospinal fluid (CSF) leak following surgery and...function improved by one Nurick's grade in 5 of the 7 patients...patients regarding the risks of s." Muthukumar and colleagues...
New narcolepsy study results reported from E.Y. Joo et al.
Biotech Week; 1/6/2010; 734 words; ...into gray matter, white matter, and cerebrospinal fluid (CSF). These segmented images were then smoothed using a 12...6):552-558). For additional information, contact S.B. Hong, Sungkyunkwan UniversitySchool Medical, Samsung...
Studies from University of Virginia have provided new data on cancer vaccines.
Cancer Vaccine Week; 1/4/2010; 1355 words; ...colony-stimulating factor (GM-CSF) administered locally together...local administration of GM-CSF augments immunogenicity of a...emulsified in incomplete Freund's adjuvant, with or without 110 mu g GM-CSF. Among 119 evaluable patients...
BioVex Appoints Tim Hanke as VP Commercial Operations.
Business Wire; 1/4/2010; 872 words; ...preparing for the commercialization of BioVex's investigational product, OncoVEX (GM-CSF). OncoVEX(GM-CSF) is currently in a pivotal Phase 3 study...hematological malignancies. About OncoVEX (GM-CSF) OncoVEX (GM-CSF) is a first in class...
Recent News Articles
- Swedish Likvor gets 2nd order for CSF dynamics device.(Brief article)
Nordic Business Report - December 11, 2009 - Building a CSF framework for CRM implementation.
Journal of Database Marketing & Customer Strategy Management - December 01, 2009 - BioVex Completes $70 Million Financing to Conclude Pivotal Study With Its Pioneering Cancer Treatment, OncoVEX (GM-CSF).
PR Newswire - November 10, 2009 - BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology.
PR Newswire - November 02, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning